ABOS — Acumen Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $122.96m
- $9.48m
- 14
- 37
- 57
- 27
Annual cashflow statement for Acumen Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.33 | -101 | -42.9 | -52.4 | -102 |
| Depreciation | |||||
| Non-Cash Items | -0.432 | 82.3 | 3.55 | 5.26 | 4.28 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.307 | 0.298 | 3.99 | 3.87 | 11.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -7.45 | -18 | -35.2 | -43.1 | -86.2 |
| Capital Expenditures | — | -0.04 | -0.161 | -0.021 | -0.016 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -104 | 39.3 | -172 | 48 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | — | -104 | 39.2 | -172 | 48 |
| Financing Cash Flow Items | — | — | — | -0.476 | -0.23 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 44.7 | 200 | 3.91 | 152 | 6.93 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 37.2 | 78.4 | 7.94 | -63 | -31.3 |